SOTIO is a biotechnology company developing a next generation Active Cellular Immunotherapy based on activated dendritic cells for the treatment of cancer and autoimmune diseases. SOTIO continues to develop new therapies to address unmet medical needs using its immunotherapy platform and proprietary cell-based technologies.
The company is looking for talented, motivated, dynamic employees to join its international team, who will have the opportunity to utilize and further develop their own abilities.
Last week was into the clinical trials of Phase II of the ovarian programme successfully enrolled the first patient. The patient was accepted into